Let's Make A Deal! 5 Tactics for Becoming a Better Negotiator — Part III
29 May, 2020Every negotiation is unique, and the tactics outlined here will not apply to every business situation. But these best practices make for a good foundation.
Insight on What Matters - So You Can Transform Your Business.
Every negotiation is unique, and the tactics outlined here will not apply to every business situation. But these best practices make for a good foundation.
Every negotiation is unique, and the tactics outlined here will not apply to every business situation. But these best practices make for a good foundation.
GlaxoSmithKline CEO Andrew Witty once commented on the high cost of drug development, saying, “If you stop failing so often, you massively reduce the cost of drug development.” So, why do clinical trials fail, and what can be done about it?
Navigating cross-border M&A transactions has always been fraught with nuances and challenges, but what does it mean when the global economy is affected adversely by a worldwide pandemic?
Virtual data rooms are being used more frequently for bankruptcy transactions amid shelter-in-place orders.
As of May 5, 2017 submission of NDAs, ANDAs and BLAs to the Center for Drug Evaluation and Research (CDER) using the eCTD format became mandatory. For commercial INDs and Master Files the deadline is May 5, 2018.
But how do you know if your company is ready to go public? Here are 8 things to evaluate before considering taking your company public.
electing the right CRO to manage a clinical trial can be a critical decision in the program’s successful outcome. With so many CROs to choose from, what kind of evaluation criteria should be used?
In advance of the webinar, we sat down with Javier to discuss some of the nuances of structuring earnouts in M&A transactions and the implications for both the buyer and seller.
Everything you need to know about the Federal Anti-Kickback Statute and the Beneficiary Inducement Statute and how it affects your patient engagement program.